Defective CD8+CD28- regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy

Clinical and Experimental Immunology

Volumn 174, Issue 1, 2013, Pages 18-26

  Ceeraz, S ^a   Hall, C ^a   Choy, E H ^b   Spencer, J ^a   Corrigall, V M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti TNF therapy; CD8+ T cells; Immunotherapy; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

CD28 ANTIGEN; INTERLEUKIN 10; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SUPPRESSOR CELL;

ANTI-TNF THERAPY; CD8+ T CELLS; IMMUNOTHERAPY; REGULATORY T CELLS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIGENS, CD28; ANTIGENS, CD8; CELL CULTURE TECHNIQUES; COCULTURE TECHNIQUES; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; MALE; METHOTREXATE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883606628     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12161     Document Type: Article

References (27)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85:307-310.
2. Ponchel F, Morgan AW, Bingham SJ etal. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002; 100:4550-4556.
3. Ehrenstein MR, Evans JG, Singh A etal. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-285.
4. Davila E, Kang YM, Park YW etal. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. J Immunol 2005; 174:7292-7301.
5. Filaci G, Fenoglio D, Fravega M etal. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179:4323-4334.
6. Colovai AI, Mirza M, Vlad G etal. Regulatory CD8+CD28- T cells in heart transplant recipients. Hum Immunol 2003; 64:31-37.
7. Tulunay A, Yavuz S, Direskeneli H, Eksioglu-Demiralp E. CD8+CD28-, suppressive T cells in systemic lupus erythematosus. Lupus 2008; 17:630-637.
8. Fagnoni FF, Vescovini R, Mazzola M etal. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 1996; 88:501-507.
9. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50:2775-2785.
10. Goronzy JJ, Shao L, Weyand CM. Immune aging and rheumatoid arthritis. Rheum Dis Clin North Am 2010; 36:297-310.
11. Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology 2008; 47:753-759.
12. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001; 167:3231-3238.
13. Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H. Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 2005; 7:S4-14.
14. Endharti AT, Rifa IM, Shi Z etal. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol 2005; 175:7093-7097.
15. Tuettenberg A, Huter E, Hubo M etal. The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. J Immunol 2009; 182:3349-3356.
16. Rajasingh J, Bord E, Luedemann C etal. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J 2006; 20:2112-2114.
17. Huizinga TW, Keijsers V, Yanni G etal. Are differences in interleukin 10 production associated with joint damage? Rheumatology 2000; 39:1180-1188.
18. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97:2027-2037.
19. Filaci G, Bacilieri S, Fravega M etal. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001; 166:6452-6457.
20. Seo SK, Choi JH, Kim YH etal. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10:1088-1094.
21. Kim YO, Kim HJ, Kim SK, Chung JH, Hong SJ. Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis. Clin Chem Lab Med 2010; 48:345-353.
22. Kong EK, Prokunina-Olsson L, Wong WH etal. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005; 52:1058-1062.
23. Pulle G, Vidric M, Watts TH. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 2006; 176:2739-2748.
24. Choi BK, Bae JS, Choi EM etal. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 2004; 75:785-791.
25. Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB×NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 2008; 180:2069-2080.
26. Venigalla RK, Tretter T, Krienke S etal. Reduced CD4+, CD25- T cell sensitivity to the suppressive function of CD4+, CD25high, CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum 2008; 58:2120-2130.
27. Lawson JM, Tremble J, Dayan C etal. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 2008; 154:353-359.